《大行報告》瑞銀:友邦(01299.HK)第三季新業務價值略勝預期 評級「買入」
瑞銀發表研究報告指出,友邦(01299.HK)第三季新業務價值以固定匯率基準計按年升7%,按實質匯率計升1%,略勝預期,顯示公司第三季強勁勢頭,新業務價值在所有主要細分市場(內地、香港及大部分東盟市場)及分銷渠道都有增長。當中,儘管受疫情影響,友邦中國新業務價值仍按年增長6%,顯著優於內地同行。至於澳門對香港業務增長帶來有力支持。
該行認為,友邦回購額度為100億美元,而截至10月底公司已執行約23億美元的股票回購,意味著仍有充足的空間支持股價。該行另相信友邦的資本具韌性,於中國的執行力及潛在增長復甦尚未於股價反映,維持對其「買入」評級,目標價100元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.